Granegis (Granisetron)

Granegis is a prescription medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist. It is supplied in oral form and is marketed in the European Union. Granisetron works by blocking serotonin receptors in the central nervous system to reduce nausea and vomiting associated with chemotherapy or surgery. The drug is typically prescribed by healthcare professionals and requires a prescription in most countries.

Granegis is indicated for the prevention and treatment of nausea and vomiting related to specific medical procedures.

- Chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Post‑operative nausea and vomiting (PONV) following surgical procedures. - Nausea associated with radiation therapy. - Nausea caused by diagnostic procedures that use emetogenic agents.

The safety profile of granisetron includes both common and less frequent adverse events, most of which are mild and transient.

Common: - Headache. - Constipation. - Dizziness. - Fatigue.

Serious: - QT interval prolongation. - Severe allergic reaction (anaphylaxis). - Serotonin syndrome (rare).

Before initiating therapy with Granegis, clinicians should evaluate several precautionary factors to ensure safe use.

- Assess cardiac history, especially for patients with known QT prolongation. - Use cautiously in patients with electrolyte disturbances (e.g., low potassium or magnesium). - Evaluate renal and hepatic function; dose adjustment may be required in severe impairment. - Consider alternative antiemetics in patients with known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Discuss potential risks with pregnant or breastfeeding women, as safety data are limited. - Monitor for signs of severe constipation or bowel obstruction during treatment.

Granisetron may interact with other medications, influencing its efficacy or safety profile.

Avoid: - Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics). - Combination with other 5‑HT3 antagonists, as this provides no added benefit and may increase toxicity.

Use with caution: - Co‑administration with drugs that affect electrolyte balance (e.g., diuretics). - Use with CYP3A4 inhibitors or inducers, which could alter granisetron plasma levels. - Concomitant use with serotonergic agents (e.g., SSRIs) requires monitoring for serotonin syndrome.